Viewing Study NCT05191004

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:58 PM
Ignite Modification Date: 2026-01-03 @ 6:19 AM
Study NCT ID: NCT05191004
Status: WITHDRAWN
Last Update Posted: 2023-07-11
First Post: 2021-12-22
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
Sponsor: Nuvation Bio Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Advanced Breast Cancer View
None Metastatic Breast Cancer View
None Breast Cancer View
None Breast Carcinoma View
None Cancer of the Breast View
None Cancer of Breast View
None Malignant Tumor of Breast View
None Breast Tumor View
Keywords:

Keywords

Keyword Brief Keyword Text View
None HER2- View
None Phase 1 View
None Phase 2 View
None metastatic breast cancer View
None advanced breast cancer View
None hormone receptor positive View
None HR+ View
None human epidermal growth factor receptor 2 negative View
None HR+ HER2- View
None estrogen receptor positive View
None ER+ View
None NUV-422 View
None fulvestrant View
None CDK View
None CDK inhibition View
None CDK2/4/6 View